Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4611]

ESMO 2019: Two studies show CDK4/6 inhibitors improve overall survival in advanced breast cancer

ESMO 2019: Two studies show CDK4/6 inhibitors improve overall survival in advanced breast cancer

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary

ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Scientists tackle potential drug resistance by using new single-cell genetic method

Scientists tackle potential drug resistance by using new single-cell genetic method

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated...

Promising prostate cancer drug candidates identified

Promising prostate cancer drug candidates identified

More from ecancer